BASEL, July 8 — Against the backdrop of a rapidly aging global population, the business of extending human life has quietly become one of the most significant growth sectors in modern biotechnology and consumer health. The global longevity market — a sprawling industry that encompasses dietary supplements, diagnostic testing, and experimental therapies designed to slow or reverse the biological processes of aging — was valued at approximately $25 billion in 2023, according to data from Grand View Research.
Industry analysts project the market will expand at a compound annual growth rate of 8.5 percent from 2024 through 2030, a trajectory that reflects both scientific ambition and demographic necessity. What is at stake is nothing less than the reshaping of healthcare, pensions, and the very structure of society as the world’s wealthiest nations confront an unprecedented wave of older citizens.
The U.S. Census Bureau projects that the number of Americans aged 65 and older will reach 73 million by 2030, a sharp increase from 54 million in 2020. That demographic shift alone is driving demand for products and services that promise to extend not just lifespan but what researchers call healthspan — the years of life lived in good health.
The players and the science
Among the established names in the sector is the Life Extension Foundation, founded in 1980, which has long supplied vitamins and nutritional supplements to a devoted customer base. A newer generation of companies is taking a more molecular approach. Elysium Health, founded in 2014 by Leonard Guarente at the Massachusetts Institute of Technology, develops supplements targeting cellular aging pathways, building on decades of academic research into the biology of aging.
In the corridors of biotechnology finance, one of the most closely watched companies has been Unity Biotechnology, founded in 2011. In 2021, the firm raised $125 million in an initial public offering to develop senolytic drugs — a class of experimental medicines designed to selectively eliminate senescent, or aging, cells that accumulate in tissues and are thought to drive inflammation and age-related disease.
The IPO signaled investor appetite for therapies that go beyond symptom management to address aging itself as a treatable condition. The financial commitment from the public sector is substantial. The U.S. National Institutes of Health spent approximately $3.8 billion on aging research in 2022, according to the National Institute on Aging.
That funding underpins a vast ecosystem of academic laboratories and clinical trials, many of which are exploring the fundamental mechanisms of cellular deterioration.
A niche market with global reach
Beyond the laboratories and corporate boardrooms, a smaller but telling segment of the longevity economy has emerged: longevity tourism. This industry, which includes clinics offering advanced diagnostics, cellular therapies, and bespoke health regimens in countries such as Switzerland and Japan, was valued at $500 million in 2022. The figure, while modest compared to the broader market, illustrates the willingness of affluent consumers to travel internationally for interventions that promise to slow the clock.
Switzerland, with its long tradition of luxury medical tourism and permissive regulatory environment for certain experimental treatments, has become a particular hub. Japanese clinics, drawing on that country’s deep cultural emphasis on healthy aging and its world-leading life expectancy, offer another destination for those seeking cutting-edge preventive care.
The wider picture is one of convergence. Demographic pressure, scientific progress, and consumer demand are aligning in ways that make longevity one of the most dynamic frontiers in global business. The companies that succeed in this space will need to navigate not only complex biology but also regulatory frameworks that vary sharply from country to country, and a public that is both hopeful and skeptical of promises to extend life.
As the 2020s progress, the question is no longer whether the longevity market will grow, but how fast, and which players will emerge as the dominant forces in an industry that touches the most fundamental human concern of all.
